Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

Trial Profile

An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epinephrine (Primary)
  • Indications Chronic urticaria
  • Focus Therapeutic Use
  • Sponsors ARS Pharmaceuticals

Most Recent Events

  • 15 Apr 2025 Status changed from planning to not yet recruiting.
  • 20 Mar 2025 According to an ARS Pharmaceuticals media release, company plans to initiate a Phase 2b clinical trial in the second quarter of 2025 and the trial is expected to enroll patients in the U.S. and Europe, with topline data anticipated in early 2026.
  • 13 Nov 2024 According to an ARS Pharmaceuticals media release, the Phase 2b trial is expected to begin in early 2025, followed by a potential single pivotal efficacy trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top